ArticleOpen medicine (Warsaw, Poland)2026
TyG index combined with BMI predicts metabolism dysfunction-associated fatty liver disease in patients with type 2 diabetes.
Article in Open medicine (Warsaw, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To explore the predictive capacity of the TyG index (triacylglycerol-glucose index) in conjunction with BMI for diagnosing MAFLD among patients with type 2 diabetes mellitus (T2DM). Methods: A retrospective study of 356 consecutive type-2 diabetes patients followed by the Endocrinology Department from May 2022 to May 2024 was studied. Participants were divided into MAFLD and non-MAFLD groups, and the association and predictive accuracy of the TyG index were evaluated using logistic regression and ROC curve analyses. Results: Significant variations in the incidence of MAFLD were observed across the quartiles Q1 (TyG<8.98), Q2 (8.98≤TyG<9.36), Q3 (9.36≤TyG<9.94), and Q4 (TyG≥9.94) (p<0.001). The formula log (p)=-22.549+0.385 * BMI + 1.3708 * TyG index illustrated that the TyG index and BMI are predictive of the likelihood of MAFLD in patients with T2DM. Furthermore, the TyG index and BMI were strongly correlated with MAFLD, evidenced by an area under the curve of 0.868 (95 % CI [0.829, 0.907], p<0.001), a sensitivity of 83.0 %, and a specificity of 77.8 %. Conclusions: The TyG index is significantly associated with the risk of developing MAFLD in individuals with type 2 diabetes, and its predictive utility is markedly enhanced when BMI is incorporated.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.